evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

283 questions · 299 findings · 27 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 74 · 24.7%GRADE not reported 27 · 9%Very low 77 · 25.8%Low 82 · 27.4%Moderate 28 · 9.4%High 11 · 3.7%

Low molecular weight heparin vs placebo or no prophylaxis

Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes frequency of adverse events ( compared with heparin alone (very low certainty).

1 finding from 1 review

Heparin prophylaxis vs no prophylaxis

All‐cause mortality

Heparin prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

2 findings from 1 review